NZ708028A - N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors - Google Patents

N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Info

Publication number
NZ708028A
NZ708028A NZ708028A NZ70802813A NZ708028A NZ 708028 A NZ708028 A NZ 708028A NZ 708028 A NZ708028 A NZ 708028A NZ 70802813 A NZ70802813 A NZ 70802813A NZ 708028 A NZ708028 A NZ 708028A
Authority
NZ
New Zealand
Prior art keywords
trka kinase
thiourea
pyrrolidinyl
guanidine
pyrazolyl
Prior art date
Application number
NZ708028A
Other languages
English (en)
Inventor
Shelley Allen
Gabrielle R Kolakowski
Barbara Brandhuber
Timothy Kercher
Shannon Winski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of NZ708028A publication Critical patent/NZ708028A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Shaping Metal By Deep-Drawing, Or The Like (AREA)
NZ708028A 2012-11-13 2013-11-12 N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors NZ708028A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725913P 2012-11-13 2012-11-13
PCT/US2013/069729 WO2014078323A1 (en) 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ708028A true NZ708028A (en) 2018-12-21

Family

ID=49667600

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ708028A NZ708028A (en) 2012-11-13 2013-11-12 N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Country Status (32)

Country Link
US (2) US9896435B2 (OSRAM)
EP (2) EP2922844B1 (OSRAM)
JP (3) JP6316834B2 (OSRAM)
KR (1) KR102181915B1 (OSRAM)
CN (2) CN104781255B (OSRAM)
AU (2) AU2013344943B2 (OSRAM)
BR (1) BR112015010875B1 (OSRAM)
CA (1) CA2890876C (OSRAM)
CL (1) CL2015001261A1 (OSRAM)
CY (1) CY1120099T1 (OSRAM)
DK (1) DK2922844T3 (OSRAM)
ES (2) ES2664331T3 (OSRAM)
HR (1) HRP20180331T1 (OSRAM)
HU (1) HUE038512T2 (OSRAM)
IL (1) IL238496B (OSRAM)
LT (1) LT2922844T (OSRAM)
ME (1) ME02990B (OSRAM)
MX (2) MX374242B (OSRAM)
MY (1) MY178262A (OSRAM)
NO (1) NO2876058T3 (OSRAM)
NZ (1) NZ708028A (OSRAM)
PH (1) PH12015500939B1 (OSRAM)
PL (1) PL2922844T3 (OSRAM)
PT (1) PT2922844T (OSRAM)
RS (1) RS57001B1 (OSRAM)
RU (1) RU2677667C2 (OSRAM)
SG (1) SG11201503728XA (OSRAM)
SI (1) SI2922844T1 (OSRAM)
SM (1) SMT201800169T1 (OSRAM)
UA (1) UA116455C2 (OSRAM)
WO (1) WO2014078323A1 (OSRAM)
ZA (1) ZA201503587B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RU2664541C2 (ru) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
ES2664331T3 (es) * 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RS57036B1 (sr) 2013-11-28 2018-05-31 Kyorin Pharmaceutical Co Ltd Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom 1 (fprl-1)
PT3154959T (pt) * 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EP3722441A1 (en) 2015-06-01 2020-10-14 Loxo Oncology Inc. Method of diagnosing a cancer for a treatment with a trk inhibitor
EP3330256B1 (en) 2015-07-07 2021-06-16 Shionogi & Co., Ltd. HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. Trk阻害薬耐性がんにおける点変異およびそれに関連する方法
WO2017135399A1 (ja) * 2016-02-04 2017-08-10 塩野義製薬株式会社 TrkA阻害活性を有する含窒素複素環および炭素環誘導体
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2019026646A (ja) * 2017-08-03 2019-02-21 塩野義製薬株式会社 含窒素複素環および炭素環誘導体を含有する、疼痛の治療および/または予防用医薬組成物
JP6986565B2 (ja) 2017-09-29 2021-12-22 田辺三菱製薬株式会社 光学活性ピロリジン化合物及びその製造方法
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
MA50456A (fr) 2017-10-26 2020-09-02 Array Biopharma Inc Formulations d'un inhibiteur de kinase trk macrocyclique
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EA202092094A1 (ru) 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
US11932652B2 (en) 2018-07-12 2024-03-19 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN112979615B (zh) * 2019-12-17 2024-08-09 上海医药集团股份有限公司 一种喹唑啉脲类化合物、其制备方法、制备中间体、药物组合物及应用
MX2022008930A (es) * 2020-01-22 2022-10-18 Benevolentai Bio Ltd Composiciones farmaceuticas y sus usos.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4323353A4 (en) * 2021-04-12 2025-04-02 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
CN113278409B (zh) * 2021-06-22 2022-04-29 西南石油大学 一种高温酸化缓蚀剂
CN114031556B (zh) * 2021-11-08 2023-03-31 温州大学 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法
CA3267500A1 (en) 2022-09-19 2024-03-28 Basf Se AZOLE PESTICIDE COMPOUNDS
WO2024240213A1 (zh) * 2023-05-23 2024-11-28 上海海雁医药科技有限公司 稠合三环取代的异噁唑烷基脲衍生物、其药物组合物及应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ299242A (en) 1995-09-11 1997-12-19 Nihon Nohyaku Co Ltd N-phenyl-n'-(phenyl substituted imidazol-5-yl, -oxazol-4-yl, and -thiazol-4-yl)urea derivatives
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
CA2308428A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
CA2356263C (en) 1998-12-25 2009-04-21 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6410533B1 (en) 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
EP1296978A2 (en) 2000-06-30 2003-04-02 Bristol-Myers Squibb Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
SE0104248D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
JP4498133B2 (ja) 2002-07-02 2010-07-07 シェーリング コーポレイション 新規神経ペプチドyy5レセプターアンタゴニスト
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2005024755A2 (en) 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
PL2017265T3 (pl) 2003-06-12 2011-11-30 Abbvie Inc Związki z pierścieniami skondensowanymi hamujące receptor waniloidowy podtypu 1 (VR1)
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
JP4573223B2 (ja) 2004-01-23 2010-11-04 東レ・ファインケミカル株式会社 光学活性trans−4−アミノ−1−ベンジル−3−ピロリジノールの製造方法
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
US20080081833A1 (en) 2004-12-20 2008-04-03 Astrazeneca Ab Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors
US20070078121A1 (en) 2004-12-23 2007-04-05 Flynn Daniel L Enzyme modulators and treatments
WO2006081034A2 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2007059202A2 (en) 2005-11-15 2007-05-24 Bayer Healthcare Ag Pyrazolyl urea derivatives useful in the treatment of cancer
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2008006979A (es) 2005-12-01 2009-01-14 Bayer Healthcare Llc Compuestos de urea utiles en el tratamiento contra el cancer.
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
WO2008021859A1 (en) 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2481736A1 (en) 2007-04-20 2012-08-01 Deciphera Pharmaceuticals, LLC. Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
ITMI20071731A1 (it) 2007-09-06 2009-03-07 Univ Degli Studi Genova Nuovi derivati ureici dell'acido 1h-pirazol-4-carbossilico con attivita inibente nei confronti della chemiotassi di neutrofili
JP5492194B2 (ja) * 2008-05-13 2014-05-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
US8592454B2 (en) 2008-09-19 2013-11-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
BRPI0920306A2 (pt) 2008-10-09 2019-09-24 Hoffmann La Roche derivados de n-benzil pirrolidina
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
CA2743553C (en) 2008-11-19 2017-03-14 Merial Limited Dimeric 1-arylpyrazole derivatives
NZ593937A (en) 2008-12-08 2014-05-30 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
CA2753061C (en) 2009-02-19 2016-08-09 Alexandros Makriyannis Novel hetero pyrrole analogs acting on cannabinoid receptors
TW201103943A (en) 2009-04-27 2011-02-01 Shionogi & Co Urea derivative having pi3k inhibitory activity
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2771612A1 (en) 2009-09-18 2011-03-24 Zalicus Pharmaceuticals Ltd. Selective calcium channel modulators
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
SI2712358T1 (sl) * 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
EP2900223B1 (en) 2012-09-28 2017-10-25 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Erk阻害剤である新規化合物
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RU2664541C2 (ru) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
ES2664331T3 (es) 2018-04-19
DK2922844T3 (en) 2018-03-05
PT2922844T (pt) 2018-04-02
RU2015122414A (ru) 2017-01-10
RS57001B1 (sr) 2018-05-31
SMT201800169T1 (it) 2018-05-02
HK1215438A1 (en) 2016-08-26
EP2922844B1 (en) 2018-01-10
CY1120099T1 (el) 2018-12-12
AU2017206195B2 (en) 2019-01-03
AU2013344943A1 (en) 2015-06-04
PL2922844T3 (pl) 2018-06-29
CN107857755A (zh) 2018-03-30
CN104781255A (zh) 2015-07-15
RU2677667C2 (ru) 2019-01-18
IL238496B (en) 2018-02-28
KR20150084047A (ko) 2015-07-21
MX365733B (es) 2019-06-12
PH12015500939B1 (en) 2018-03-14
WO2014078323A1 (en) 2014-05-22
AU2013344943B2 (en) 2017-06-29
CA2890876C (en) 2021-01-19
JP2016501191A (ja) 2016-01-18
SI2922844T1 (en) 2018-04-30
CL2015001261A1 (es) 2015-09-25
CN107857755B (zh) 2020-10-27
AU2017206195A1 (en) 2017-08-03
BR112015010875B1 (pt) 2022-05-03
LT2922844T (lt) 2018-03-26
US9896435B2 (en) 2018-02-20
JP6316834B2 (ja) 2018-04-25
HUE038512T2 (hu) 2018-10-29
BR112015010875A2 (pt) 2017-07-11
SG11201503728XA (en) 2015-06-29
EP2922844A1 (en) 2015-09-30
US10851080B2 (en) 2020-12-01
MX2019006834A (es) 2019-09-06
CN104781255B (zh) 2017-10-24
US20160280682A1 (en) 2016-09-29
JP2019081786A (ja) 2019-05-30
EP3409670B1 (en) 2020-09-09
KR102181915B1 (ko) 2020-11-23
EP3409670A1 (en) 2018-12-05
IL238496A0 (en) 2015-06-30
BR112015010875A8 (pt) 2019-10-01
CA2890876A1 (en) 2014-05-22
HRP20180331T1 (hr) 2018-05-04
MX374242B (es) 2025-03-05
JP2018048176A (ja) 2018-03-29
UA116455C2 (uk) 2018-03-26
ZA201503587B (en) 2020-11-25
ES2834027T3 (es) 2021-06-16
MX2015006046A (es) 2015-12-01
JP6482629B2 (ja) 2019-03-13
MY178262A (en) 2020-10-07
NO2876058T3 (OSRAM) 2018-06-30
US20180179182A1 (en) 2018-06-28
ME02990B (me) 2018-10-20
PH12015500939A1 (en) 2015-06-29

Similar Documents

Publication Publication Date Title
NZ708028A (en) N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
PH12015500938A1 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
PH12013502319A1 (en) Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
CL2015000942A1 (es) Compuestos de benceno sustituido.
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CL2015001374A1 (es) Compuestos derivados de 2-(metilamino)-n-(2-oxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3il)propanamida; composicion farmaceutica; y su uso en el tratamiento terapeutico o profilactico del cancer.
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
CR20150300A (es) Compuestos de n-pirrolidinil, n´-pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2020 BY COMPUTER PACKAGES INC

Effective date: 20191018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2022 BY THOMSON REUTERS

Effective date: 20211002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2023 BY THOMSON REUTERS

Effective date: 20221003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2024 BY THOMSON REUTERS

Effective date: 20231002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2025 BY THOMSON REUTERS

Effective date: 20241002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2026 BY THOMSON REUTERS

Effective date: 20251001